|
View: |
Part 1: Document Description
|
|
Citation |
|
|---|---|
|
Title: |
All associated data including underlying and extended data and supplementary materials for the publication: McLean et al. The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions. Wellcome Open Research, 2021 |
|
Identification Number: |
doi:10.7910/DVN/D0ZXJ5 |
|
Distributor: |
Harvard Dataverse |
|
Date of Distribution: |
2021-12-13 |
|
Version: |
1 |
|
Bibliographic Citation: |
Guerin, Philippe, 2021, "All associated data including underlying and extended data and supplementary materials for the publication: McLean et al. The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions. Wellcome Open Research, 2021", https://doi.org/10.7910/DVN/D0ZXJ5, Harvard Dataverse, V1 |
|
Citation |
|
|
Title: |
All associated data including underlying and extended data and supplementary materials for the publication: McLean et al. The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions. Wellcome Open Research, 2021 |
|
Identification Number: |
doi:10.7910/DVN/D0ZXJ5 |
|
Authoring Entity: |
Guerin, Philippe (University of Oxford) |
|
Distributor: |
Harvard Dataverse |
|
Access Authority: |
Guerin, Philippe |
|
Depositor: |
Guerin, Philippe |
|
Date of Deposit: |
2021-12-13 |
|
Holdings Information: |
https://doi.org/10.7910/DVN/D0ZXJ5 |
|
Study Scope |
|
|
Keywords: |
Medicine, Health and Life Sciences, Medicine, Health and Life Sciences, Living systematic review, COVID-19, SARS2-CoV2, Coronavirus, Clinical trials, Emerging infections |
|
Abstract: |
This repository contains the following extended data: - PRISMA 2020 flow diagram - PRISMA 2020 Checklist - Priority drugs variable dictionary - Source data from ICTRP |
|
Methodology and Processing |
|
|
Sources Statement |
|
|
Data Access |
|
|
Notes: |
CC0 Waiver |
|
Other Study Description Materials |
|
|
Related Publications |
|
|
Citation |
|
|
Bibliographic Citation: |
McLean ARD, Rashan S, Tran L, Arena L, Lawal A, Maguire BJ, Adele S, Sitsofe Antonio S, Brack M, Caldwell F, Carrara VI3, Charles R, Citarella BW, Epie TB, Feteh VF, Kennon K, Makuka GJ, Ngu R, Nwosu A-P, Obiesie S, Ogbonnaa-Njoku C, Paul P, Richmond C, Singh-Phulgenda S, Strudwick S, Tyrrell CSB, Stepniewska K, Strub-Wourgaft N, White NJ, Guérin PJ. The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions. WellcomeOpen. 2021 In press |
|
Label: |
2021-11-19_COVID-19_LSR_PriorityDrug_PRISMA_22NOV21.docx |
|
Notes: |
application/vnd.openxmlformats-officedocument.wordprocessingml.document |
|
Label: |
Copy of COVID_LSR_PriorityDrugPaper_Consolidation_20210819.xlsx |
|
Notes: |
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet |
|
Label: |
Priority_Drug_IDDO_Variable_Dictionary.xlsx |
|
Notes: |
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet |
|
Label: |
PRISMA_2020_checklist.docx |
|
Notes: |
application/vnd.openxmlformats-officedocument.wordprocessingml.document |